NEW YORK, June 27, 2011 /PRNewswire/ — Reportlinker.com
announces that a new market research report is available in its
HIV across the seven major markets is largely dominated by two
companies: Gilead Sciences and ViiV Healthcare. The growing
dominance of convenient one-pill once-daily regimens will
increasingly pressure companies to collaborate and co-formulate
their marketed and/or pipeline HIV drugs into fixed dose
combinations (FDCs) to remain successful in a tight HIV market.
Features and benefits
* In-depth discussion of portfolios and strategies of key HIV
* Discussion of future strategic opportunities to achieve
success in a crowded HIV market.
* Review of corporate strategies in HIV.
With Gilead and ViiV Healthcare clearly dominating the HIV
market, the remaining companies active in the field have much
smaller HIV portfolios. An emerging HIV treatment trend towards
nuc-sparing regimens offers opportunities for smaller players to
form new vertical collaborations and to diversify the HIV
With its blockbuster products Truvada (tenofovir disoproxil